Q3 2024 Vivoryon Therapeutics NV Earnings Call Transcript
Key Points
- Vivoryon Therapeutics NV (STU:05Y) reported positive kidney function data from the VIVA-MIND Phase 2 study, showing significant improvement in eGFR versus placebo.
- The company presented kidney outcome results at ASN Kidney Week, receiving positive feedback from the nephrology community.
- Vivoryon hosted a virtual kidney disease KOL event, highlighting the potential of varoglutamstat in addressing key inflammatory and fibrotic pathways in kidney disease.
- The company plans to start a Phase 2 study in diabetic kidney disease (DKD) in 2025, leveraging strong data from VIVIAD and VIVA-MIND studies.
- Vivoryon has extended its financial guidance, expecting cash and cash equivalents to fund operations into the third quarter of 2025.
- Vivoryon reported a net loss of EUR17.4 million for the first nine months of 2024, consistent with the same period in 2023.
- The company's cash and cash equivalents decreased significantly from EUR28.6 million at the end of 2023 to EUR12.5 million as of September 30, 2024.
- The VIVA-MIND study was terminated early due to lack of efficacy in Alzheimer's disease, impacting the planned patient enrollment.
- There is a need for additional funding and partnerships to support future clinical studies and potential expansion into orphan kidney diseases.
- The company faces challenges in maintaining momentum in Alzheimer's research due to the shift in focus towards kidney disease.
Good afternoon and thank you for joining us today to discuss the company's third quarter 2024 result operational update. This morning, Vivoryon issued a press release reporting its nine-month 2024 financial results and also provide an update on our progress which was marked by compelling kidney function data as well as execution of important steps in implementing our strategy to advance varoglutamstat and kidney disease. This press release is posted on Vivoryon's website at www.vivoryon.com.
On the call with me today are Vivoryon's Chief Executive Officer, Frank Weber; our Chief Business Officer, Michael Schaeffer, is also available for Q&A. We will begin today's call with opening remarks from myself, giving you an overview of the key highlights from the third quarter and post period update. After which, we will move to Frank, who will provide some details on the exciting news update we announced yesterday, which is the positive kidney function
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
